Gyre Therapeutics' Q3 Net Income Soars, Cash Reserves Bolstered

TL;DR

**GYRE's cash position looks strong after a public offering, but the nine-month profit dip suggests underlying operational challenges despite Q3's net income jump.**

AI Summary

GYRE THERAPEUTICS, INC. reported a net income of $5.9 million for the three months ended September 30, 2025, a significant increase from $2.9 million in the same period of 2024. Revenues also grew to $30.6 million for the quarter, up from $25.5 million year-over-year. For the nine months ended September 30, 2025, net income was $11.2 million, a decrease from $17.3 million in the prior year, despite revenues increasing slightly to $79.4 million from $77.9 million. The company's cash and cash equivalents surged to $40.4 million as of September 30, 2025, from $11.8 million at December 31, 2024, largely due to $24.1 million in net cash provided by financing activities, including a $23.0 million public offering. Operating expenses rose to $23.6 million for the quarter and $68.0 million for the nine months, driven by increased selling and marketing and general and administrative costs. The accumulated deficit improved to $66.7 million from $73.5 million at year-end 2024. The company maintains a 69.7% indirect interest in Gyre Pharmaceuticals, a commercial-stage biopharmaceutical company in China focused on anti-fibrotic drugs.

Why It Matters

This filing reveals a mixed financial picture for Gyre Therapeutics. While the significant increase in cash and cash equivalents to $40.4 million and the improved Q3 net income are positive for investors, the nine-month net income decline from $17.3 million to $11.2 million warrants closer scrutiny. The company's focus on anti-fibrotic drugs in China, through its 69.7% interest in Gyre Pharmaceuticals, places it in a competitive and growing market, but also exposes it to specific regulatory and economic risks in the PRC. Employees and customers benefit from a more liquid company, but the long-term profitability trend needs to stabilize to ensure sustained growth and market confidence against larger, more established biotechnology competitors.

Risk Assessment

Risk Level: medium — The company reported an accumulated deficit of $66.7 million as of September 30, 2025, indicating historical losses. While current liquidity is strong with $40.4 million in cash and cash equivalents, the nine-month net income decreased from $17.3 million in 2024 to $11.2 million in 2025, suggesting potential challenges in sustained profitability despite revenue growth. The company's significant operations in the PRC also expose it to geopolitical and regulatory risks.

Analyst Insight

Investors should monitor GYRE's ability to translate its increased cash reserves into sustained profitability and positive cash flow from operations, especially given the nine-month net income decline. Evaluate the impact of increased selling and marketing expenses on future revenue growth and watch for further developments in its anti-fibrotic drug pipeline. Consider the risks associated with its substantial operations in China.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$79.4M

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

$11.2M

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$40.4M

revenue Growth

1.9%

Revenue Breakdown

Key Numbers

• $40.4M — Cash and cash equivalents (Increased from $11.8M at December 31, 2024, indicating improved liquidity.)
• $30.6M — Revenues for Q3 2025 (Increased from $25.5M in Q3 2024, showing quarterly growth.)
• $5.9M — Net income for Q3 2025 (Increased from $2.9M in Q3 2024, a significant quarterly improvement.)
• $79.4M — Revenues for nine months ended Sep 30, 2025 (Slightly increased from $77.9M in the prior year period.)
• $11.2M — Net income for nine months ended Sep 30, 2025 (Decreased from $17.3M in the prior year period, indicating a year-to-date decline.)
• $66.7M — Accumulated deficit (Improved from $73.5M at December 31, 2024, reducing historical losses.)
• $24.1M — Net cash provided by financing activities (Primarily from a $23.0M public offering, significantly boosting cash reserves.)
• 90,890,381 — Common shares outstanding (As of September 30, 2025, reflecting share issuance activities.)
• 69.7% — Indirect interest in Gyre Pharmaceuticals (Represents the company's controlling stake in its key operating subsidiary.)
• $6.6M — Net cash provided by operating activities (For the nine months ended September 30, 2025, a positive shift from the prior year.)

Key Players & Entities

• GYRE THERAPEUTICS, INC. (company) — Registrant and commercial-stage biotechnology company
• Beijing Continent Pharmaceuticals Co., Ltd. (company) — 69.7% indirectly owned subsidiary, d/b/a Gyre Pharmaceuticals Co., Ltd.
• GNI USA, Inc. (company) — Majority shareholder of Gyre Pharmaceuticals
• GNI Group Ltd. (company) — Indirectly wholly owns GNI USA, Inc.
• The Nasdaq Capital Market (regulator) — Exchange where GYRE Common Stock is registered
• Securities and Exchange Commission (regulator) — Regulates the company's filings and reporting
• Delaware (regulator) — State of incorporation for Gyre Therapeutics, Inc.
• People's Republic of China (regulator) — Country where Gyre Pharmaceuticals is registered and operates
• Executive Chairman of Gyre's Board of Directors (person) — Serves as Gyre's Interim Chief Executive Officer and part of the CODM
• Gyre's Chief Operating Officer (person) — Serves as Gyre Pharmaceuticals' General Manager and part of the CODM

FAQ

Risk Factors

• Dependence on Gyre Pharmaceuticals [high — operational]: The company's financial performance is heavily reliant on its 69.7% indirect interest in Gyre Pharmaceuticals, a commercial-stage biopharmaceutical company. Any operational or market challenges faced by Gyre Pharmaceuticals could significantly impact GYRE THERAPEUTICS' results.
• Accumulated Deficit [medium — financial]: Despite an improvement to $66.7 million from $73.5 million at year-end 2024, the company still carries a substantial accumulated deficit. This indicates a history of net losses and may impact future profitability and investor confidence.
• Reliance on Financing Activities [medium — financial]: The significant increase in cash to $40.4 million from $11.8 million was largely driven by $24.1 million in net cash from financing, including a $23.0 million public offering. Continued reliance on external financing may dilute existing shareholders or increase debt.
• Biopharmaceutical Regulatory Environment [high — regulatory]: As a company with a significant stake in a biopharmaceutical firm, GYRE THERAPEUTICS is subject to the stringent and evolving regulatory landscape of drug development and commercialization. Delays or failures in regulatory approvals for Gyre Pharmaceuticals' products could severely impact revenue and market access.
• Competition in Anti-fibrotic Drugs [medium — market]: Gyre Pharmaceuticals operates in the competitive anti-fibrotic drug market. The success of its products depends on differentiation, efficacy, and market adoption against existing and emerging therapies.

Industry Context

GYRE THERAPEUTICS operates within the biopharmaceutical sector, with a strategic focus on anti-fibrotic drugs through its significant stake in Gyre Pharmaceuticals in China. This market is characterized by high R&D costs, long development cycles, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and market access in a competitive landscape.

Regulatory Implications

The company's reliance on Gyre Pharmaceuticals exposes it to the complex and evolving regulatory frameworks governing drug approval and commercialization in China and potentially other markets. Any changes in regulatory policy or adverse decisions on drug applications could significantly impact the business.

What Investors Should Do

1. Monitor Gyre Pharmaceuticals' clinical trial progress and regulatory filings.
2. Analyze the sustainability of the quarterly revenue and net income growth.
3. Evaluate the company's cash burn rate and future financing needs.

Key Dates

• 2025-09-30: Quarterly Financial Reporting — Reported $5.9M net income and $30.6M revenue for Q3 2025, showing strong quarterly performance.
• 2025-09-30: Balance Sheet Date — Cash reserves increased significantly to $40.4M, primarily due to a public offering.
• 2025-09-30: Nine Months Financial Reporting — Reported $11.2M net income and $79.4M revenue for the nine months ended Sep 30, 2025, with a year-to-date net income decrease.
• 2024-12-31: Prior Year End Balance Sheet — Cash position was $11.8M and accumulated deficit was $73.5M, providing a baseline for current improvements.

Glossary

Accumulated Deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical profitability and its progress towards overall profitability, currently at $66.7M.)

Net cash provided by financing activities

The net amount of cash generated or used by a company's financing activities, such as issuing debt or equity, or paying dividends. (Highlights the impact of capital raising activities on liquidity, with $24.1M provided in the nine months ended Sep 30, 2025, largely from a public offering.)

Indirect interest

Ownership stake in a company that is not direct but held through another entity. (GYRE THERAPEUTICS holds a 69.7% indirect interest in Gyre Pharmaceuticals, its primary operating entity.)

Commercial-stage biopharmaceutical company

A company that has at least one drug approved and marketed, generating revenue from sales. (Describes the operational status of Gyre Pharmaceuticals, the company in which GYRE THERAPEUTICS has a significant stake.)

Year-Over-Year Comparison

Compared to the prior year, GYRE THERAPEUTICS shows a mixed performance. While Q3 2025 revenue and net income saw significant quarterly increases ($30.6M and $5.9M respectively), the nine-month period reveals a slight revenue increase ($79.4M vs $77.9M) but a notable decrease in net income ($11.2M vs $17.3M). The company has substantially improved its liquidity, with cash rising from $11.8M to $40.4M, largely due to a public offering, and has reduced its accumulated deficit from $73.5M to $66.7M.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share GYRE The Nasdaq Capital M

Filing Documents

• gyre-20250930.htm (10-Q) — 3970KB
• gyre-ex31_1.htm (EX-31.1) — 19KB
• gyre-ex31_2.htm (EX-31.2) — 19KB
• gyre-ex32_1.htm (EX-32.1) — 15KB
• gyre-ex32_2.htm (EX-32.2) — 15KB
• 0001193125-25-272383.txt ( ) — 16103KB
• gyre-20250930.xsd (EX-101.SCH) — 1659KB
• gyre-20250930_htm.xml (XML) — 3810KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 2 Item 1.

Financial Statements

Financial Statements: 2 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 2 Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2025 and 2024 (unaudited) 3 Condensed Consolidated Statements of Convertible Preferred Stock and Equity for the three and nine months ended September 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (unaudited) 5 Notes to the Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 41

OTHER INFORMATION

PART II. OTHER INFORMATION 42 Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 42 Item 3. Defaults Upon Senior Securities 42 Item 4. Mine Safety Disclosures 42 Item 5. Other Information 42 Item 6. Exhibits 43 Exhibit Index 43

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FIN ANCIAL STATEMENTS

ITEM 1. FIN ANCIAL STATEMENTS Gyre Therapeutics, Inc. Condensed Consolidat ed Balance Sheets (In thousands, except share and per share amounts) September 30, 2025 December 31, 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 40,402 $ 11,813 Short-term bank deposits 19,647 14,858 Notes receivable 693 4,373 Accounts receivable, net 25,877 19,589 Other receivables from GNI 230 230 Inventories 8,854 6,337 Receivable from GCBP — 4,961 Prepaid assets and other current assets 2,873 2,625 Total current assets 98,576 64,786 Property and equipment, net 23,608 23,880 Intangible assets, net 4,847 273 Deferred tax assets 6,714 5,619 Long-term certificates of deposit 20,317 24,568 Other assets, noncurrent 5,322 6,280 Total assets $ 159,384 $ 125,406 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 556 $ 108 Contract liabilities 58 61 Due to related parties 228 227 Accrued expenses and other current liabilities 11,799 10,615 Income tax payable 2,646 2,831 Operating lease liabilities, current 626 713 CVR derivative liability — 4,961 Total current liabilities 15,913 19,516 Operating lease liabilities, noncurrent 539 885 Deferred government grants 866 928 Warrant liability, noncurrent 3,224 5,668 Other noncurrent liabilities 1,427 7 Total liabilities 21,969 27,004 Commitments and Contingencies (Note 12) Stockholders' equity: Common stock, $ 0.001 par value, 400,000,000 shares authorized; 90,890,381 shares and 86,307,544 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 91 86 Additional paid-in capital 167,134 136,185 Statutory reserve 3,098 3,098 Accumulated deficit ( 66,703 ) ( 73,453 ) Accumulated other comprehensive loss ( 1,700 ) ( 2,597 ) Total Gyre stockh

View Full Filing

View this 10-Q filing on SEC EDGAR